Logo do repositório
 
Publicação

SARS-CoV-2 Seroprevalence among healthcare workers compared to the general population, 2021-22

2025-09-03Documento de conferência Acesso aberto
Ver registo simples
dc.contributor.authorGaio, Vânia
dc.contributor.authorAmaral, Palmira
dc.contributor.authorSantos, Ana João
dc.contributor.authorHenriques, Camila
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorMachado, Ausenda
dc.contributor.authorGuiomar, Raquel
dc.date.accessioned2026-03-04T15:23:51Z
dc.date.available2026-03-04T15:23:51Z
dc.date.issued2025-09-03
dc.descriptionAbstract publicado em: Gaceta Sanit. 2025;39(Supl. 2):646.
dc.description.abstractHealthcare workers (HCWs) are essential as frontline responders during infectious disease health emergencies. Protecting them is crucial to ensure their health, maintain continuous patient care, and prevent transmission to patients. This study aimed to estimate the SARS-CoV-2 seroprevalence trend among HCWs from a Portuguese hospital cohort between May 2021 and June 2022. It also aimed to compare it with the seroprevalence trend in the general population aged 40-49. Additionally, the characterization of HCWs with seroconversion was performed based on their positivity for anti-nucleocapsid (Anti-N) IgG antibodies. As part of a vaccine effectiveness study, HCWs were screened for anti-RBD/Spike IgG antibodies against SARS-CoV-2 in three time points: May–July 2021, September–November 2021, and May–June 2022. At the last moment, Anti-N IgG antibodies were also assessed. To compare with data on the general population, we used results from three National Serological Surveys (NSS) phases (February–March 2021, September–November 2021, and April–June 2022) focusing on the 40–49 age group, the most representative among HCW. HCW characteristics were compared according to anti-N IgG seropositivity using the Chi-square and Mann-Whitney tests, assuming a significance level of 0.05. HCWs screening at the 3 moments included 909, 474, and 67 individuals respectively with SARS-CoV-2 seroprevalence was 86%, 90%, and 100%, respectively. These seroprevalences were similar to those found in the Portuguese general population, except for the first period (86% versus 18.8% in the general population, age group 40-49 years). At the last moment, the post-infection seroprevalence (anti-N IgG antibodies) was higher among HCWs than in the general population (41% versus 27%). A lower age and direct contact with COVID-19 patients were associated with anti-N IgG antibody positivity. The increasing trend of seroprevalence among HCWs follows the same trend in the general population. Although the time points differ, in the first moment, higher SARS-CoV-2 seroprevalence was probably linked to priority vaccine uptake. In the third moment, the higher post-infection seroprevalence among HCWs suggests a raised exposure and infection incidence in HCWs following the Omicron wave. Given the decline in COVID-19 vaccination coverage among HCWs in the post-pandemic period, ongoing monitoring of seroprevalence and COVID-19 infection rates in this group remains crucial.eng
dc.description.sponsorshipVEBIS Lot2
dc.identifier.urihttp://hdl.handle.net/10400.18/11136
dc.language.isoeng
dc.peerreviewedn/a
dc.relation.hasversionhttps://gacetasanitaria.org/en-congresos-xliii-reunion-anual-sociedad-espanola-177-sesion-cr-covid--8699-sars-cov-seroprevalence-among-healthcare-workers-107017-pdf
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectSARS-CoV-2
dc.subjectHealthcare Workers
dc.subjectVEBIS Lot2
dc.subjectISN-COVID-19
dc.subjectDeterminantes de Saúde
dc.subjectEstado de Saúde e de Doença
dc.subjectInfecções Respiratórias
dc.titleSARS-CoV-2 Seroprevalence among healthcare workers compared to the general population, 2021-22eng
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferenceDate2025-09-03
oaire.citation.conferencePlaceLas Palmas de Gran Canaria, Espanha
oaire.citation.titleXX Congress of the Portuguese Epidemiology Association (APE) / XLIII Annual Meeting of the Spanish Society of Epidemiology (SEE), 2–5 September 2025
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameGaio
person.familyNameGuiomar
person.givenNameVânia
person.givenNameRaquel
person.identifier.ciencia-idA71A-17AF-30C7
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.orcid0000-0001-7626-4991
person.identifier.orcid0000-0002-4563-6315
person.identifier.scopus-author-id56080468200
relation.isAuthorOfPublication59791814-187c-4b34-b3a2-6ad67a213814
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublication.latestForDiscovery59791814-187c-4b34-b3a2-6ad67a213814

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
CR26_Comunicacao_707_VaniaGaio_versão reduzida.pdf
Tamanho:
1.08 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Apresentações orais em encontros internacionais
DDI - Apresentações orais em encontros internacionais